En studie för att utvärdera effektiviteten och säkerheten hos fenebrutinib jämfört med teriflunomid vid återfallande multipel skleros (RMS) (FENhance)
En fas III multicenter randomiserad, dubbelblind, dubbeldummy, parallellgruppsstudie för att utvärdera effektiviteten och säkerheten av fenebrutinib jämfört med teriflunomid hos vuxna patienter med återfallande multipel skleros
A study to evaluate the efficacy and safety of fenebrutinib on disability progression and relapse rate in adult participants with RMS. Eligible participants will be randomized in a 1:1 ratio to receive either fenebrutinib or teriflunomide. At the end of the double-blind treatment (DBT) phase (after disclosure of the DBT results), the Sponsor will determine whether or not to initiate the open-label extension (OLE) phase of the study.
Studieöversikt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Studietyp
Studietyp
Inskrivning (Faktisk)
Inskrivning
Fas
Fas
- Fas 3
Kontakter och platser
Studieorter
-
-
-
Buenos Aires, Argentina, C1424
- Centro de Especialidades Neurológicas y Rehabilitación - CENyR
-
Buenos Aires, Argentina, C1405BCH
- IME - Instituto Médico Especializado
-
Buenos Aires, Argentina, C1182ACA
- Neurologia Infantil Buenos Aires (NIBA)
-
C. A. B. A., Argentina, C1055AAF
- CIER
-
Rosario, Argentina, 2000
- Diagnostico Medico Oroño
-
San Juan, Argentina, J5400CEP
- Cer San Juan
-
San Miguel de Tucumán, Argentina, T4000AXL
- Centro de Investigaciones Médicas Tucuman
-
-
-
-
-
Santiago de los Caballeros, Dominikanska republiken, 51000
- NeuroINC
-
Santo Domingo, Dominikanska republiken, 10210
- Hospital Padre Billini
-
-
-
-
-
Helsinki, Finland, 00290
- Helsinki University Central Hospital
-
-
-
-
Alabama
-
Birmingham, Alabama, Förenta staterna, 35233
- University of Alabama Birmingham
-
Homewood, Alabama, Förenta staterna, 35209
- Alabama Neurology Associates
-
-
Arizona
-
Phoenix, Arizona, Förenta staterna, 85032
- Center for Neurology and Spine - Phoenix - Hunt - PPDS
-
-
California
-
Carlsbad, California, Förenta staterna, 92011
- Profound Research, LLC
-
Irvine, California, Förenta staterna, 92697
- University of California Irvine
-
Pasadena, California, Förenta staterna, 91106
- Quantum Clinical Research, Inc
-
-
Colorado
-
Aurora, Colorado, Förenta staterna, 80045
- University of Colorado Denver
-
Denver, Colorado, Förenta staterna, 80209
- Mountain View Clinical Research
-
Fort Collins, Colorado, Förenta staterna, 80528
- Advanced Neurology of Colorado, LLC
-
-
Florida
-
Maitland, Florida, Förenta staterna, 32751
- Neurology Associates, PA; Research Department
-
-
Illinois
-
Highland Park, Illinois, Förenta staterna, 60035
- NorthShore University HealthSystem
-
-
Indiana
-
Fort Wayne, Indiana, Förenta staterna, 46805
- Fort Wayne Neurological Center
-
-
Louisiana
-
Baton Rouge, Louisiana, Förenta staterna, 70810
- The NeuroMedical Center
-
Shreveport, Louisiana, Förenta staterna, 71103
- Ochsner LSU Health
-
-
Maryland
-
Baltimore, Maryland, Förenta staterna, 21287
- Johns Hopkins University School Of Medicine; Outpatient Center
-
-
Massachusetts
-
Worcester, Massachusetts, Förenta staterna, 01655
- University of Massachusetts Medical School
-
-
Michigan
-
Detroit, Michigan, Förenta staterna, 48202
- Henry Ford Health System
-
-
Missouri
-
St Louis, Missouri, Förenta staterna, 63110
- Washington University School of Medicine
-
-
New Jersey
-
Teaneck, New Jersey, Förenta staterna, 07666
- Holy Name Hospital; Institute For Clinical Research
-
-
New Mexico
-
Albuquerque, New Mexico, Förenta staterna, 87131
- University of New Mexico; MS Specialty Clinic
-
-
Ohio
-
Centerville, Ohio, Förenta staterna, 45459
- Miami Valley Hospital South; Dayton Physician's Office
-
Columbus, Ohio, Förenta staterna, 43214
- OhioHealth
-
Columbus, Ohio, Förenta staterna, 43235
- The Boster Center for Multiple Sclerosis a Singlepoint Healthcare Company
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Förenta staterna, 73104
- Oklahoma Medical Research Foundation; MS Center of Excellence
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, Förenta staterna, 18015
- St. Luke's University Health network
-
-
South Carolina
-
Greenville, South Carolina, Förenta staterna, 29605
- Premier Neurology
-
-
Tennessee
-
Knoxville, Tennessee, Förenta staterna, 37920
- New Orleans Center for Clinical Research
-
-
Texas
-
Plano, Texas, Förenta staterna, 75024
- North Texas Institute of Neurology and Headache NextStage Clinical Research Clinic
-
Sherman, Texas, Förenta staterna, 75092
- Texas Institute for Neurological Disorders
-
-
Virginia
-
Vienna, Virginia, Förenta staterna, 22182
- Multiple Sclerosis Center of Greater Washington
-
-
Washington
-
Kirkland, Washington, Förenta staterna, 98034
- Evergreen MS Center
-
-
Wisconsin
-
Milwaukee, Wisconsin, Förenta staterna, 53215
- Wheaton Franciscan Healthcare - St. Francis Outpatient Center; Center for Neurological Disorders
-
-
-
-
-
Tbilisi, Georgien, 0179
- Khechinashvili University Hospital
-
Tbilisi, Georgien, 0114
- New Hospitals
-
Tbilisi, Georgien, 0114
- Pineo Medical Ecosystem
-
Tbilisi, Georgien, 0160
- MediClab Georgia
-
Tbilisi, Georgien, 0159
- St. Michael hospital
-
-
-
-
-
Hong Kong, Hong Kong
- Pamela Youde Nethersole Eastern Hospital
-
Shatin, New Territories, Hong Kong
- Prince of Wales Hospital
-
-
-
-
Apulia
-
Foggia, Apulia, Italien, 71100
- AO.U. Policlinico Riuniti Foggia
-
-
Campania
-
Naples, Campania, Italien, 80131
- AOU Seconda Università degli Studi
-
Naples, Campania, Italien, 80138
- AOU Policlinico - Università L. Vanvitelli
-
-
Emilia-Romagna
-
Parma, Emilia-Romagna, Italien, 43126
- A.O.U. di Parma
-
-
Lazio
-
Rome, Lazio, Italien, 00185
- Policlinico Umberto I
-
Rome, Lazio, Italien, 00189
- Azienda Ospedaliera Sant'Andrea
-
Rome, Lazio, Italien, 00133
- Policlinico Tor Vergata Dip. Neuroscienze-Clinica Neurologica-UOSD Sclerosi Multipla
-
-
Lombardy
-
Bergamo, Lombardy, Italien, 24127
- ASST PAPA GIOVANNI XXIII Neurologia USS Malattie Autoimmuni Centro Sclerosi Multipla
-
Milan, Lombardy, Italien, 20132
- IRCCS Ospedale San Raffaele
-
-
Piedmont
-
Mondovì (CN), Piedmont, Italien, 12084
- Ospedale Regina Montis Regalis
-
-
Sicily
-
Catania, Sicily, Italien, 95123
- AOU Policlinico V. Emanuele - P.O G. Rodolico
-
-
Veneto
-
Padova, Veneto, Italien, 35128
- Azienda Ospedaliera di Padova
-
-
-
-
-
Nairobi, Kenya, 00100
- The Aga Khan University-Kenya.
-
-
-
-
-
Beijing, Kina
- Beijing Tiantan Hospital,Capital Medical University
-
Beijing, Kina, 100034
- Peking University First Hospital
-
Changchun, Kina, 130021
- the First Hospital of Jilin University
-
Changsha, Kina, 410008
- Xiangya Hospital Central South University
-
Chengdu, Kina, 610041
- West China Hospital, Sichuan University
-
Chongqing, Kina, 400016
- The First Affiliated Hospital, Chongqing Medical University
-
Guangzhou, Kina, 510080
- The First Affiliated Hospital of Sun Yat-sen University
-
Guangzhou, Kina, 510260
- The second Affiliated Hospital of Guangzhou Medical University
-
Guiyang, Kina
- The affiliated Hospital of Guiyang Medical College
-
Kunming, Kina, 650021
- The First People?s Hospital of Yunnan Province
-
Shijiazhuang, Kina, 05000
- The Second Hospital of Hebei Medical University
-
Suzhou, Kina, 215031
- The First Affiliated Hospital of Soochow University
-
Taiyuan, Kina
- 1st Affiliated Hospital of Shanxi Medical University
-
Tianjin, Kina, 300052
- Tianjin Medical University General Hospital
-
Wuhan, Kina, 430030
- Tongji Hospital Tongji Medical College Huazhong University of Science and Technology
-
Xi'an, Kina
- Tangdu Hospital, The Fourth Military Medical University
-
Ürümqi, Kina, 830000
- Xinjiang People Hospital
-
-
-
-
Coahuila
-
Saltillo, Coahuila, Mexiko, 25050
- Clinical Research Institute Saltillo
-
-
Mexico CITY (federal District)
-
Mexico City, Mexico CITY (federal District), Mexiko, 03100
- Grupo Medico de Investigacion Clinica Multidisciplinaria
-
Mexico City, Mexico CITY (federal District), Mexiko, 03100
- Health Pharma Professional Research
-
-
Sinaloa
-
Culiacán, Sinaloa, Mexiko, 80020
- Neurociencias Estudios Clinicos S.C.
-
-
Tlaxcala
-
Mexico, Tlaxcala, Mexiko, 06726
- Hospital General de Mexico
-
-
-
-
-
Sittard-Geleen, Nederländerna, 6162 BG
- Zuyderland Medisch Centrum - Sittard Geleen
-
-
-
-
-
Shtip, Nordmakedonien, 2000
- Clinical Hospital Stip
-
Skopje, Nordmakedonien, 1000
- PHO General City Hospital 8th September Center for dialysis
-
Skopje, Nordmakedonien, 1000
- University Clinic for Neurology - Skopje
-
-
-
-
-
Bellavista, Peru, Callao 2
- Hospital IV Alberto Sabogal Sologuren
-
La Victoria, Lima, Peru, Lima 13
- Hospital Nacional Guillermo Almenara Irigoyen
-
Lima, Peru, Lima 29
- Hospital Maria Auxiliadora
-
Lima, Peru, 15018
- Hospital Nacional Dos de Mayo
-
Lima, Peru, Lima 01
- Clinica Internacional Sede Lima
-
Pueblo Libre, Peru, Lima 21
- Clinica Centenario Peruano Japonesa
-
-
-
-
-
?ory, Polen, 44-240
- ProNeuro Centrum Medyczne
-
Bydgoszcz, Polen, 85-796
- Neurocentrum Bydgoszcz sp. z o.o
-
Katowice, Polen, 40-568
- Care Clinic
-
Krosno, Polen, 38-400
- MT Medic Krosno
-
Lodz, Polen, 90-324
- Centrum Neurologii Krzysztof Selmaj
-
Lublin, Polen, 20-492
- Rodzinne Centrum Medyczne Lubimed.pl
-
Warsaw, Polen, 02-957
- Instytut Psychiatrii i Neurologii II Klinika Neurologiczna
-
Zabrze, Polen, 41-800
- IBISMED Wielospecjalistyczne Centrum Medyczne
-
-
-
-
-
Braga, Portugal, 4710-243
- Hospital de Braga
-
Coimbra, Portugal, 3000-075
- HUC
-
Lisbon, Portugal, 1500-650
- Hospital da Luz
-
Lisbon, Portugal, 1169-050
- Hospital Santo Antonio dos Capuchos
-
Porto, Portugal, 4200-319
- Hospital de Sao Joao
-
Porto, Portugal, 4099-001
- Hospital Geral de Santo Antonio
-
Santa Maria da Feira, Portugal, 4520-211
- Centro Hospitalar Entre o Douro e Vouga E.P.E. - Hospital de São Sebastião
-
-
-
-
-
Kirov, Ryssland, 610007
- Center of Cardiology and Neurology
-
Novosibirsk, Ryssland, 630007
- FSBIH Siberian Regional Medical Centre of FMBA of Russia
-
-
Bashkortostan Republic
-
Ufa, Bashkortostan Republic, Ryssland, 450005
- Republican clinical hospital named after G.G. Kuvatov
-
-
Sankt-Peterburg
-
Saint Petersburg, Sankt-Peterburg, Ryssland, 194291
- Leningrad Regional Clinical Hospital
-
Saint Petersburg, Sankt-Peterburg, Ryssland, 197022
- Pavlov State Medical Uni
-
-
Ulyanovsk Oblast
-
Ulyanovsk, Ulyanovsk Oblast, Ryssland, 432063
- Ulyanovsk Regional Clinical Hospital
-
-
-
-
-
Bern, Schweiz, 3010
- Inselspital Bern Medizin Neurologie
-
Lugano, Schweiz, 6903
- Ospedale Regionale di Lugano - Civico
-
-
-
-
-
Belgrade, Serbien, 11000
- University Clinical Center of Serbia
-
-
-
-
-
Barcelona, Spanien, 08035
- Hospital Universitari Vall d'Hebron
-
Madrid, Spanien, 28034
- Hospital Ramon y Cajal
-
Madrid, Spanien, 28007
- Hospital General Universitario Gregorio Marañon
-
Madrid, Spanien, 28040
- Fundacion Jimenez Diaz
-
Madrid, Spanien, 28006
- Hospital Universitario de la Princesa
-
Málaga, Spanien, 29010
- Hospital Regional Universitario de Malaga ? Hospital General
-
Seville, Spanien, 41009
- Hospital Universitario Virgen Macarena
-
-
Barcelona
-
L'Hospitalet de Llobregat, Barcelona, Spanien, 08907
- Hospital Universitari de Bellvitge
-
-
Madrid
-
Pozuelo de Alarcón, Madrid, Spanien, 28223
- Hospital Quiron de Madrid
-
-
Murcia
-
EL Palmar (EL Palmar), Murcia, Spanien, 30120
- Hospital Universitario Virgen de Arrixaca
-
-
Pontevedra
-
Vigo, Pontevedra, Spanien, 36213
- Hospital Alvaro Cunqueiro
-
-
-
-
-
Mannouba, Tunisien, 2010
- Hopital Razi
-
Monastir, Tunisien, 5000
- Fattouma Bourguiba Hospital
-
Sfax, Tunisien, 3029
- Hospital Habib Bourguiba
-
-
-
-
-
Berlin, Tyskland, 13347
- Jüdisches Krankenhaus Berlin
-
Böblingen, Tyskland, 71034
- Studienzentrum Dr. Bischof GmbH
-
Dresden, Tyskland, 01307
- Universitätsklinikum "Carl Gustav Carus", Zentrum für Klinische Neurowissenschaften
-
Giessen, Tyskland, 35385
- Universitätsklinikum Gießen und Marburg GmbH
-
Kiel, Tyskland, 24105
- Uniklinik Schleswig-Holstein
-
Stuttgart, Tyskland, 70174
- Praxis Dr. med. Andreas Kowalik, Arzt für Neurologie und Psychiatrie
-
Tübingen, Tyskland, 72076
- Universitätsklinikum Tübingen, Zentrum für Neurologie
-
Ulm, Tyskland, 89081
- Universitätsklinikum Ulm
-
Westerstede, Tyskland, 26655
- Studienzentrum Nordwest Dr med Joachim Springub Herr Wolfgang Schwarz
-
-
-
-
-
Dnipro, Ukraina, 49027
- SI USSRI of Medical and Social Problems of Disabilities of MOHU
-
Kharkiv, Ukraina, 61068
- Ams of Ukraine
-
Kyiv, Ukraina, 03037
- Medical Center of Private Execution First Private Clinic
-
Kyiv, Ukraina, 02123
- Medical Center Dopomoga Plus
-
Lviv, Ukraina, 79010
- Lviv Regional Clinical Hospital
-
Lviv, Ukraina, 79029
- "Neurofocus" LLC
-
Odesa, Ukraina, 65117
- Odesa Regional Clinical Hospital
-
Vinnytsi, Ukraina, 21009
- Medical Clinical Research Center of Medical Center LLC Health Clinic
-
Zaporizhzhya, Ukraina, 69600
- Municipal Non-profit Enterprise Zaporizhzhya Regional Hospital Zaporizhzhya Regional Council
-
Zaporizhzhya, Ukraina, 69035
- LCC "Medical center "Unimed"
-
-
KIEV Governorate
-
Vinnytsia, KIEV Governorate, Ukraina, 21009
- Salutem Medical Center
-
-
Tavria Okruha
-
Dnipro, Tavria Okruha, Ukraina
- Separated structural unit ?University hospital? of Dnipro State Medical University
-
-
-
-
-
Budapest, Ungern, 1033
- Clinexpert Kft.
-
Budapest, Ungern, 1044
- S-Medicon Egeszsegugyi Szolgaltato Kft.
-
Eger, Ungern, 3300
- Markhot Ferenc Oktatokorhaz és Rendelointezet
-
Kistarcsa, Ungern, 2143
- Pest Megyei Flor Ferenc Korhaz
-
Szeged, Ungern, 6725
- Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ
-
-
Deltagandekriterier
Urvalskriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Expanded Disability Status Scale (EDSS) score of 0 - 5.5 at screening
- A diagnosis of RMS in accordance with the revised 2017 McDonald Criteria
- Ability to complete the 9-Hole Peg Test (9-HPT) for each hand in < 240 seconds
- Ability to perform the Timed 25-Foot Walk Test (T25FWT) in < 150 seconds
- For female participants of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and refrain from donating eggs
- For male participants: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and refrain from donating sperm
OLE Inclusion Criteria:
- Completed the DBT phase of the study (remaining on study treatment; no other disease-modifying therapy (DMT) administered) and who, in the opinion of the investigator, may benefit from treatment with fenebrutinib
- Participants randomized to the teriflunomide treatment arm during the DBT phase must undergo the accelerated teriflunomide elimination procedure (ATEP) prior to the first administration of open-label fenebrutinib
- For female participants of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and refrain from donating eggs
- For male participants: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and refrain from donating sperm
Exclusion Criteria:
- Disease duration of > 10 years from the onset of symptoms and an EDSS score at screening < 2.0
- Female participants who are pregnant or breastfeeding, or intending to become pregnant
- Male participants who intend to father a child during the study
- A diagnosis of primary progressive multiple sclerosis (PPMS) or non-active secondary progressive multiple sclerosis (SPMS)
- Any known or suspected active infection at screening, including but not limited to a positive screening test for hepatitis B (HBV) and hepatitis C (HCV), an active or latent or inadequately treated infection with tuberculosis (TB), a confirmed or suspected progressive multifocal leukoencephalopathy (PML)
- History of cancer including hematologic malignancy and solid tumors within 10 years of screening
- Known presence of other neurological disorders, that could interfere with the diagnosis of MS or assessments of efficacy or safety during the study and clinically significant cardiovascular, psychiatric, pulmonary, renal, hepatic, endocrine, metabolic or gastrointestinal (GI) disease
- Rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption
- Hypoproteinemia
- Acute liver disease
- Chronic liver disease unless considered stable for > 6 months
- Presence of cirrhosis (Child-Pugh Class A, B, or C) or Gilbert's Syndrome
- Participants with significantly impaired bone marrow function or significant anemia, leukopenia, neutropenia or thrombocytopenia
- Any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study
- History of alcohol or other drug abuse within 12 months prior to screening
- History of or currently active primary or secondary (non-drug-related) immunodeficiency, including known history of human immunodeficiency virus (HIV) infection
- Inability to complete an MRI scan
- Adrenocorticotropic hormone or systemic corticosteroid therapy within 4 weeks prior to screening (inhaled and topical corticosteroids are allowed)
- Receipt of a live-attenuated vaccine within 6 weeks prior to randomization
- Any previous treatment with immunomodulatory or immunosuppressive medication without an appropriate washout period
OLE Exclusion Criteria:
- Acute liver disease
- Chronic liver disease unless considered stable for > 6 months
- Cirrhosis (Child-Pugh Class A, B, or C)
- Gilbert's syndrome
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Antal vapen
Vapen och interventioner
Deltagargrupp / ArmDeltagargrupp / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Experimentell: Fenebrutinib
Participants will receive oral (PO) fenebrutinib, with teriflunomide-matching placebo. |
Participants will receive fenebrutinib. Participants will receive teriflunomide-matching placebo or fenebrutinib-matching placebo. |
|
Aktiv komparator: Teriflunomide
Participants will receive PO teriflunomide, with fenebrutinib-matching placebo in a blinded fashion. |
Participants will receive teriflunomide-matching placebo or fenebrutinib-matching placebo. Participants will receive teriflunomide. |
Vad mäter studien?
Primära resultatmått
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Årlig återfallsfrekvens (ARR)
Tidsram: Minst 96 veckor
|
Minst 96 veckor
|
Sekundära resultatmått
Sekundära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Tid till början av sammansatt 12-veckors bekräftad funktionsnedsättningsprogression (cCDP12)
Tidsram: Minst 96 veckor
|
Minst 96 veckor
|
|
Tid till början av sammansatt 24-veckors bekräftad funktionsnedsättningsprogression (cCDP24)
Tidsram: Minst 96 veckor
|
Minst 96 veckor
|
|
Tid till början av 12 veckors bekräftad funktionsnedsättningsprogression (CDP12)
Tidsram: Minst 96 veckor
|
Minst 96 veckor
|
|
Tid till början av 24 veckors bekräftad funktionsnedsättningsprogression (CDP24)
Tidsram: Minst 96 veckor
|
Minst 96 veckor
|
|
Plasmakoncentrationer av Fenebrutinib vid specificerade tidpunkter
Tidsram: Upp till 4,5 år
|
Upp till 4,5 år
|
|
Tid till början av sammansatt 12-veckors bekräftad progression oberoende av återfallsaktivitet (CPIRA12)
Tidsram: Minst 96 veckor
|
Minst 96 veckor
|
|
Procentandel av deltagare med biverkningar (AEs)
Tidsram: Upp till 4,5 år
|
Upp till 4,5 år
|
|
Total Number of T1 Gadolinium Enhancing (Gd+) Lesions, New and/or Enlarging T2-weighted Lesions, as Detected by Magnetic Resonance Imaging (MRI)
Tidsram: Baseline, Weeks 12, 24, 48 and 96
|
Baseline, Weeks 12, 24, 48 and 96
|
|
Percentage Change in Total Brain Volume From Week 24 as Assessed by MRI
Tidsram: From Week 24 to Week 96
|
From Week 24 to Week 96
|
|
Time to Onset of 12-week Confirmed 4-point Worsening in Symbol Digit Modality Test (SDMT) Score
Tidsram: Minimum of 96 weeks
|
Minimum of 96 weeks
|
|
Change in Participant-reported Physical Impacts of Multiple Sclerosis (MS), as Measured by the Multiple Sclerosis Impact Scale (29-item), Version 2 (MSIS-29) Physical Scale
Tidsram: Baseline, Weeks 12, 24, 36, 48, 60, 72, 84 and 96
|
Baseline, Weeks 12, 24, 36, 48, 60, 72, 84 and 96
|
|
Percent Change From Baseline to Week 48 in the Concentration of Blood Neurofilament Light Chain (NfL)
Tidsram: Baseline, Week 48
|
Baseline, Week 48
|
Samarbetspartners och utredare
Sponsor
Sponsor
Utredare
Utredare
- Studierektor: Clinical Trials, Hoffmann-La Roche
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Studiestart
Primärt slutförande (Faktisk)
Primärt slutförande
Avslutad studie (Beräknad)
Avslutad studie
Studieregistreringsdatum
Först inskickad
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Första postat
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste uppdatering publicerad
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
Andra studie-ID-nummer
- GN41851
- 2019-004857-10 (EudraCT-nummer)
- 2019 (U.S.S. NIH-anslag/kontrakt)
- 2022-502609-14-00 (Ctis)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .